☰
✕

Anticonvulsants market

Anticonvulsant Drugs Market, by Drug Class (Barbiturates, Benzodiazepines, Aromatic allylic alcohols, Carboxamides, Triazine, AMPA receptor antagonists, Carbamate, Hydantoin, Fatty Acid Derivative, GABA analogs, Valproylamides, Others (Propionates, Oxazolidinediones, etc.)), by Route of Administration (Enteral, Parenteral), by Indication (Epilepsy, Neuropathic pain, Anxiety, Fibromyalgia, Bipolar Disorder, Others (Borderline personality disorder, etc.)), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Request Free Sample
  • Jan 2023
  • CMI2516
  • 170 Pages
  • Excel & Pdf
  • Pharmaceutical

Anti-seizure medications (anticonvulsants) were originally designed to treat people with epilepsy. Recurrent seizures, which are abrupt bursts of electrical activity in the brain that momentarily impair brain function, are the main signs of epilepsy. While some seizures result in difficulties such as loss of awareness or strange sensations, others cause the body to shake and twitch. Anti-epileptic drugs (AEDs) are more frequently used to treat illnesses such as epilepsy, migraine, neuropathic pain, and bipolar disorder. The drugs prescribed for anti-epileptics are categorized into three generations. The first generation of drugs includes Bromide, Phenobarbital, Primidone, Carbamazepine, and others, the second generation of drugs includes Felbamate, Lamotrigine, and Levetiracetam, and the third generation of drugs includes Lacosamide, Eslicarbazepine Acetate, Clobazam, and others

Global anticonvulsant drugs market is estimated to be valued at US$ 6,757.8 million in 2022 and is expected to reach US$ 8,030.4 million by 2030, witnessing a CAGR of 2.2% over the forecast period (2022-2030).

Figure 1. Global Anticonvulsant Drugs Market Share (%), By Region, 2022

Global Anticonvulsant Drugs Market – Drivers

The increasing number of product approvals by regulatory authorities is expected to drive the global anticonvulsant drugs market growth over the forecast period. For instance, in March 2022, Lupin, a pharmaceutical company, announced that they had received approval from the U.S. Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA), Vigabatrin for Oral Solution USP (500 mg), indicated for epilepsy.

Anticonvulsant Drugs Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 6,757.8 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 2.2% 2030 Value Projection: US$ 8,030.4 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Class: Barbiturates, Benzodiazepines, Aromatic allylic alcohols, Carboxamides, Triazine, AMPA receptor antagonists, Carbamate, Hydantoin, Fatty Acid Derivative, GABA analogs, Valproylamides, Others (Propionates, Oxazolidinediones, etc.)
  • By Route of Administration: Enteral, Parenteral
  • By Indication: Epilepsy, Neuropathic pain, Anxiety, Fibromyalgia, Bipolar Disorder, Others (Borderline personality disorder, etc.)
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Novartis AG, GSK plc., Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Zogenix, Dr. Reddy’s Laboratories Ltd., Alkem Labs, SK BIOPHARMACEUTICALS, Eisai Co., Ltd, Angelini S.p.a., Sun Pharmaceutical Industries Ltd., UCB S.A., Unichem Laboratories, Jazz Pharmaceuticals, Inc., Neuropathix, Inc., Xenon Pharmaceuticals, Inc., SK Life Science, Inc., Sumitomo Pharma Co., Ltd, and Bausch Health Companies Inc.
Growth Drivers:
  • Increasing number of drug approvals by regulatory authorities
  • Increasing government initiatives to increase awareness about epilepsy treatment
Restraints & Challenges:
  • Increasing number of product recall by regulatory authorities such as U.S. Food and Drug Administration

Figure 2. Global Anticonvulsant Drugs Market Share (%) Analysis, By Route of Administration, 2022

Global Anticonvulsant Drugs Market – Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID-19) pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors. The private healthcare sector is one of the sectors, which has been majorly impacted by the COVID-19 pandemic. The lockdown in various countries due to the COVID-19 pandemic has created an economic burden on the private healthcare sector. According to the Indian Journal of Medical Sciences published a report in 2020, the COVID-19 pandemic has affected the conduction of clinical trials due to the unavailability of trial site staff, restrictions for traveling, investigational product availability, and others.

According to National Center for Biotechnology Information (NCBI) published a report on April 29, 2020, many clinical trials suspended trial enrollment to minimize the risk of contracting COVID-19, and this has led to the delay in the activation of new clinical trials. Moreover, many companies have already missed the follow-up for the patients already in trials. Product development has experienced disruption to adjust to remote-work environments and lab capacity is reduced. Clinical trials are also being severely affected by disruptions in both new enrollments and in keeping existing patients on therapies. According to clinicaltrial.gov, as of April 2020, there were more than 2,850 trials and around 900,000 patients enrolled at trial sites in regions that were in partial or complete lockdown due to COVID-19 restrictions. While the R&D labs are currently operating at below 50% of the normal capacity across the globe. Many research centers have decided to freeze new trials and have stopped inpatient studies. Different pharmaceutical companies have also decided to delay the start of new clinical trials, suspended enrollment in some trials, and have postponed the initiation of new sites in the case of trials continuing enrollment.

Thus, the impact of the coronavirus (COVID-19) pandemic is expected to limit growth of the global anticonvulsant drugs market during the forecast period.

Global Anticonvulsant Drugs Market: Key Developments

In June 2022, the Government of Manitoba, a Canadian province, announced an annual investment of more than US$ 2.5 million in operating funding to support the establishment of the adult epilepsy surgery program, as well as the expansion of the pediatric program, which has completed about 15 surgeries per year since 2017. When the expanded program will be fully operational, around 50 epilepsy surgeries will be completed per year in Manitoba including 20 adult and 30 pediatric cases. The program, including surgeries, will be run at Health Sciences Centre (HSC) Winnipeg, a hospital in Manitoba.

Global Anticonvulsant Drugs Market: Restraint

Increasing number of product recall by regulatory authorities such U.S. Food and Drug Administration is expected to hamper the growth of anticonvulsant drugs market. For instance, in January 2022, U.S. Food and Drug Administration recalled 15,336 bottles of 200-mg carbamazepine tablets, which was manufactured by Torrent Pharmaceuticals Ltd., a pharmaceutical company. The product was recalled because samples failed to meet dissolution specifications during testing.

Global Anticonvulsant Drugs Market - Key Players

Major players operating in the global anticonvulsant drugs market include Novartis AG, GSK plc., Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Zogenix, Dr. Reddy’s Laboratories Ltd., Alkem Labs, SK BIOPHARMACEUTICALS, Eisai Co., Ltd, Angelini S.p.a., Sun Pharmaceutical Industries Ltd., UCB S.A., Unichem Laboratories, Jazz Pharmaceuticals, Inc., Neuropathix, Inc., Xenon Pharmaceuticals, Inc., SK Life Science, Inc., Sumitomo Pharma Co., Ltd, and Bausch Health Companies Inc.

 

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Drug Class
      • Market Snapshot, By Route of Administration
      • Market Snapshot, By Indication
      • Market Snapshot, By Distribution Channel
      • Market Snapshot, By Region
      • Market Opportunity Map
  3. Global Anticonvulsant Drugs Market Insights
    • Drivers
    • Restraints
    • Opportunity
    • Impact Analysis
    • Pipeline Analysis
    • PEST Analysis
    • Key Developments
    • Regulatory Scenario
    • Merger & Acquisition Scenario
    • Pricing Analysis
    • Brand Mapping
  4. Global Anticonvulsant Drugs Market- Impact of Coronavirus (Covid-19) Pandemic
    • COVID-19 Epidemiology
    • Impact On Supply And Demand
    • Impact on Clinical Trials
  5. Global Anticonvulsant Drugs Market, By Drug Class, 2017 – 2030 (US$ Million)
    • Introduction
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2017 – 2030
      • Segment Trends
    • Barbiturates
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
    • Benzodiazepines
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
    • Aromatic allylic alcohols
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
    • Carboxamides
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
    • Triazine
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
    • AMPA receptor antagonists
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
    • Carbamate
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
    • Hydantoin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
    • Fatty Acid Derivative
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
    • GABA analogs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
    • Valproylamides
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
    • Others (Propionates, Oxazolidinediones, etc.)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
  6. Global Anticonvulsant Drugs Market, By Route of Administration, 2017 – 2030 (US$ Million)
    • Introduction
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2017 – 2030
      • Segment Trends
    • Enteral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
    • Parenteral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
  7. Global Anticonvulsant Drugs Market, By Indication, 2017 – 2030 (US$ Million)
    • Introduction
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2017 – 2030
      • Segment Trends
    • Epilepsy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
    • Neuropathic pain
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
    • Anxiety
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
    • Fibromyalgia
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
    • Bipolar Disorder
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
    • Others (Borderline personality disorder, etc.)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
  8. Global Anticonvulsant Drugs Market, By Distribution Channel, 2017 – 2030 (US$ Million)
    • Introduction
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2017 – 2030
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
  9. Global Anticonvulsant Drugs Market, By Region, 2017 – 2030 (US$ Million)
    • Introduction
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2017 – 2030
      • Region at Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 – 2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017 – 2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth,  By Distribution Channel, 2017–2030, (US$ Mn)
      • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017–2030, (US$ Million)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 – 2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017 – 2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017–2030, (US$ Mn)
      • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017–2030, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 – 2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017 – 2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth,  By Distribution Channel, 2017–2030, (US$ Mn)
      • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017–2030, (US$ Million)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 – 2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017 – 2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth,  By Distribution Channel, 2017–2030, (US$ Mn)
      • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017–2030, (US$ Million)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 – 2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017 – 2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth,  By Distribution Channel, 2017–2030, (US$ Mn)
      • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017–2030, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 – 2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017 – 2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth,  By Distribution Channel, 2017–2030, (US$ Mn)
      • Market Size and Forecast By Value, and Y-o-Y Growth, By Country/Region, 2017–2030, (US$ Million)
        • South Africa
        • Central Africa
        • North Africa
  10. Company Profiles
    • Novartis AG*
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • GSK plc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Johnson & Johnson
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Teva Pharmaceutical Industries Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Pfizer, Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Zogenix
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • DR. Reddy’s Laboratories Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Alkem Labs
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • SK BIOPHARMACEUTICALS
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Eisai Co., Ltd
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Angelini S.p.a.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Sun Pharmaceutical Industries Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • UCB S.A.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Unichem Laboratories
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Jazz Pharmaceuticals, Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Neuropathix, Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Xenon Pharmaceuticals, Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • SK Life Science, Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Sumitomo Pharma Co., Ltd
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Bausch Health Companies Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
  11. Section
    • Research Methodology
    • About us

*Browse 44 market data tables and 46 figures on "Global Anticonvulsant Drugs Market” - forecast to 2030

Detailed Segmentation:

  • Global Anticonvulsant Drugs Market, By Drug Class:
    • Barbiturates
    • Benzodiazepines
    • Aromatic allylic alcohols
    • Carboxamides
    • Triazine
    • AMPA receptor antagonists
    • Carbamate
    • Hydantoin
    • Fatty Acid Derivative
    • GABA analogs
    • Valproylamides
    • Others (Propionates, Oxazolidinediones, etc.)
  • Global Anticonvulsant Drugs Market, By Route of Administration:
    • Enteral
    • Parenteral
  • Global Anticonvulsant Drugs Market, By Indication:
    • Epilepsy
    • Neuropathic pain
    • Anxiety
    • Fibromyalgia
    • Bipolar Disorder
    • Others (Borderline personality disorder, etc.)
  • Global Anticonvulsant Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Anticonvulsant Drugs Market, By Region:     
    • North America
      • By Drug Class
        • Barbiturates
        • Benzodiazepines
        • Aromatic allylic alcohols
        • Carboxamides
        • Triazine
        • AMPA receptor antagonists
        • Carbamate
        • Hydantoin
        • Fatty Acid Derivative
        • GABA analogs
        • Valproylamides
        • Others (Propionates, Oxazolidinediones, etc.)
      • By Route of Administration
        • Enteral
        • Parenteral
      • By Indication
        • Epilepsy
        • Neuropathic pain
        • Anxiety
        • Fibromyalgia
        • Bipolar Disorder
        • Others (Borderline personality disorder, etc.)
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Drug Class
        • Barbiturates
        • Benzodiazepines
        • Aromatic allylic alcohols
        • Carboxamides
        • Triazine
        • AMPA receptor antagonists
        • Carbamate
        • Hydantoin
        • Fatty Acid Derivative
        • GABA analogs
        • Valproylamides
        • Others (Propionates, Oxazolidinediones, etc.)
      • By Route of Administration
        • Enteral
        • Parenteral
      • By Indication
        • Epilepsy
        • Neuropathic pain
        • Anxiety
        • Fibromyalgia
        • Bipolar Disorder
        • Others (Borderline personality disorder, etc.)
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Class
        • Barbiturates
        • Benzodiazepines
        • Aromatic allylic alcohols
        • Carboxamides
        • Triazine
        • AMPA receptor antagonists
        • Carbamate
        • Hydantoin
        • Fatty Acid Derivative
        • GABA analogs
        • Valproylamides
        • Others (Propionates, Oxazolidinediones, etc.)
      • By Route of Administration
        • Enteral
        • Parenteral
        • By Indication
        • Epilepsy
        • Neuropathic pain
        • Anxiety
        • Fibromyalgia
        • Bipolar Disorder
        • Others (Borderline personality disorder, etc.)
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Class
        • Barbiturates
        • Benzodiazepines
        • Aromatic allylic alcohols
        • Carboxamides
        • Triazine
        • AMPA receptor antagonists
        • Carbamate
        • Hydantoin
        • Fatty Acid Derivative
        • GABA analogs
        • Valproylamides
        • Others (Propionates, Oxazolidinediones, etc.)
      • By Route of Administration
        • Enteral
        • Parenteral
      • By Indication
        • Epilepsy
        • Neuropathic pain
        • Anxiety
        • Fibromyalgia
        • Bipolar Disorder
        • Others (Borderline personality disorder, etc.)
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drug Class
        • Barbiturates
        • Benzodiazepines
        • Aromatic allylic alcohols
        • Carboxamides
        • Triazine
        • AMPA receptor antagonists
        • Carbamate
        • Hydantoin
        • Fatty Acid Derivative
        • GABA analogs
        • Valproylamides
        • Others (Propionates, Oxazolidinediones, etc.)
      • By Route of Administration
        • Enteral
        • Parenteral
      • By Indication
        • Epilepsy
        • Neuropathic pain
        • Anxiety
        • Fibromyalgia
        • Bipolar Disorder
        • Others (Borderline personality disorder, etc.)
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Class
        • Barbiturates
        • Benzodiazepines
        • Aromatic allylic alcohols
        • Carboxamides
        • Triazine
        • AMPA receptor antagonists
        • Carbamate
        • Hydantoin
        • Fatty Acid Derivative
        • GABA analogs
        • Valproylamides
        • Others (Propionates, Oxazolidinediones, etc.)
      • By Route of Administration
        • Enteral
        • Parenteral
      • By Indication
        • Epilepsy
        • Neuropathic pain
        • Anxiety
        • Fibromyalgia
        • Bipolar Disorder
        • Others (Borderline personality disorder, etc.)
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Novartis AG
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • GSK plc.
    • Johnson & Johnson
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer, Inc.
    • Zogenix
    • Dr. Reddy’s Laboratories Ltd.
    • Alkem Labs
    • SK BIOPHARMACEUTICALS
    • Eisai Co., Ltd
    • Angelini S.p.a.
    • Sun Pharmaceutical Industries Ltd.
    • UCB S.A.
    • Unichem Laboratories
    • Jazz Pharmaceuticals, Inc.
    • Neuropathix, Inc.
    • Xenon Pharmaceuticals, Inc.
    • SK Life Science, Inc.
    • Sumitomo Pharma Co., Ltd
    • Bausch Health Companies Inc.

“*” marked represents similar segmentation in other categories in the respective section.
- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global anticonvulsant drugs market during the forecast period (2022-2030)?

Global anticonvulsant drugs market is estimated to be valued at US$ 6,757.8 Million in 2022 and is expected to exhibit a CAGR of 2.2% between 2022 and 2030

What are the major factors driving the market growth?

Increasing number of drug approvals by regulatory authorities, and increasing government initiatives to increase awareness about epilepsy treatment, are major factors driving the market

Which is the major route of administration segment in the market?

Enteral segment is expected to hold largest market share due to ease of administration and increasing launches of oral drugs

What are the key factors hampering growth of the market?

Increasing number of product recall by regulatory authorities such as U.S. Food and Drug Administration

Which are the major players operating in the market?

Major players operating in the market include Novartis AG, GSK plc., Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Zogenix, Dr. Reddy’s Laboratories Ltd., Alkem Labs, SK BIOPHARMACEUTICALS, Eisai Co., Ltd, Angelini S.p.a., Sun Pharmaceutical Industries Ltd., UCB S.A., Unichem Laboratories, Jazz Pharmaceuticals, Inc., Neuropathix, Inc., Xenon Pharmaceuticals, Inc., SK Life Science, Inc., Sumitomo Pharma Co., Ltd, and Bausch Health Companies Inc.
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.
Buy Now with Special Discount
Customize Now